Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18651002 | NOTCH4 ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATING AIRWAY INFLAMMATION | April 2024 | December 2024 | Allow | 8 | 1 | 0 | No | No |
| 18619759 | TNFR2 Agonists with Improved Stability | March 2024 | September 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18695013 | COLLAGEN HYDROLYSATE FOR USE IN PREVENTION AND/OR TREATMENT OF POST INTENSIVE CARE SYNDROME (PICS) | March 2024 | December 2024 | Allow | 9 | 0 | 1 | Yes | No |
| 18587502 | BISPECIFIC ANTIBODY THAT BINDS TO CD116 AND CD131 | February 2024 | August 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18337875 | HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAME | June 2023 | March 2025 | Allow | 21 | 0 | 0 | No | No |
| 18321249 | Anti-Jagged Antibodies and Methods of Use | May 2023 | May 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18312045 | INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF | May 2023 | May 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18296510 | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION | April 2023 | May 2025 | Allow | 25 | 1 | 0 | No | No |
| 18295631 | EXOSOME FOR STIMULATING T CELL AND PHARMACEUTICAL USE THEREOF | April 2023 | October 2024 | Allow | 18 | 0 | 0 | No | No |
| 18185443 | VEGFR Fusion Protein Pharmaceutical Composition | March 2023 | February 2025 | Allow | 23 | 1 | 0 | No | No |
| 18183804 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | March 2023 | April 2025 | Allow | 25 | 1 | 1 | No | No |
| 18182829 | HUMAN OTIC PROGENITOR IDENTIFICATION AND ISOLATION | March 2023 | September 2024 | Allow | 18 | 1 | 0 | No | No |
| 18041845 | A FUSION PROTEIN COMPRISING AN ANTIGEN BINDING DOMAIN AND A CYTOKINE TRIMER DOMAIN | February 2023 | June 2024 | Allow | 16 | 1 | 0 | No | No |
| 18107386 | PREFILLED SYRINGE WITH PEGFILGRASTIM HAVING OPTIMIZED DOSE AND METHODS RELATED THERETO | February 2023 | February 2025 | Allow | 25 | 1 | 1 | No | No |
| 18006370 | IL27RAlpha Binding Molecules and Methods of Use | January 2023 | July 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17992529 | Blood Biomarkers and Diagnostic Methods for Small Vessel Diseases | November 2022 | August 2024 | Allow | 21 | 1 | 0 | No | No |
| 18047039 | ANTI-HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOF | October 2022 | November 2023 | Allow | 13 | 1 | 0 | No | No |
| 17934064 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | September 2022 | December 2024 | Allow | 27 | 0 | 1 | Yes | No |
| 17933229 | NOVEL ANTI-PAD4 ANTIBODY | September 2022 | June 2025 | Allow | 33 | 1 | 0 | No | No |
| 17931049 | OPTIMIZED ANTI-TL1A ANTIBODIES | September 2022 | October 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17816823 | IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIES | August 2022 | February 2025 | Allow | 31 | 2 | 0 | No | No |
| 17846950 | TREATMENT FOR PRIMARY AMYLOIDOSIS WITH ANTI-BCMA BINDING PROTEIN | June 2022 | October 2024 | Allow | 28 | 1 | 0 | No | No |
| 17841704 | METHODS OF PROGNOSIS AND TREATMENT | June 2022 | October 2024 | Allow | 28 | 1 | 1 | No | No |
| 17841595 | PROTEOLYTICALLY CLEAVABLE CHIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | June 2022 | March 2025 | Allow | 33 | 2 | 0 | No | No |
| 17663260 | VEGFR Fusion Protein Pharmaceutical Composition | May 2022 | March 2023 | Allow | 10 | 2 | 0 | No | No |
| 17732420 | CD137 BINDING FIBRONECTIN TYPE III DOMAINS | April 2022 | November 2024 | Allow | 31 | 2 | 1 | No | No |
| 17731976 | NUCLEIC ACID CONSTRUCT THAT ENCODES CHIMERIC RHODOPSIN | April 2022 | May 2023 | Allow | 13 | 1 | 1 | No | No |
| 17717200 | EARLY DIAGNOSIS OF INFECTIONS | April 2022 | March 2024 | Allow | 23 | 1 | 0 | No | No |
| 17716630 | METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS | April 2022 | January 2025 | Allow | 33 | 2 | 1 | No | No |
| 17701372 | SIGNATURE OF TL1A (TNFSF15) SIGNALING PATHWAY | March 2022 | December 2024 | Allow | 32 | 2 | 1 | No | No |
| 17695769 | CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN | March 2022 | September 2023 | Allow | 18 | 0 | 0 | No | No |
| 17686453 | MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT | March 2022 | June 2024 | Allow | 27 | 1 | 1 | No | No |
| 17686536 | ANTI-IL-31RA ANTIBODY-CONTAINING FORMULATIONS | March 2022 | August 2024 | Allow | 29 | 1 | 0 | No | No |
| 17682922 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | February 2022 | March 2024 | Allow | 25 | 1 | 1 | No | No |
| 17680719 | MEDICINE FOR TREATING CANCER BY ADMINISTERING A TOLL-LIKE RECEPTOR AGONIST AND LAG-3 IgG FUSION PROTEIN | February 2022 | May 2023 | Allow | 14 | 0 | 0 | No | No |
| 17672889 | ANTI-JAGGED1 ANTIGEN BINDING PROTEINS | February 2022 | September 2023 | Allow | 19 | 1 | 0 | No | No |
| 17573991 | METHODS OF ADMINISTERING ANTI-IL31A ANTIBODY-CONTAINING FORMULATIONS | January 2022 | March 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17569261 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | January 2022 | September 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17563846 | HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAME | December 2021 | November 2024 | Allow | 35 | 2 | 0 | Yes | No |
| 17561606 | COMPOSITIONS COMPRISING ALBUMIN-FMS-LIKE TYROSINE KINASE 3 LIGAND FUSION PROTEINS AND USES THEREOF | December 2021 | March 2025 | Allow | 39 | 2 | 0 | Yes | Yes |
| 17557654 | PROTEASE-ACTIVATING CD45-GATE CAR | December 2021 | April 2025 | Allow | 40 | 1 | 1 | No | No |
| 17555357 | T Cell Modulator | December 2021 | October 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17552841 | A METHOD FOR TREATING DISEASE USING FOXP3+CD4+ T CELLS | December 2021 | June 2022 | Allow | 6 | 3 | 0 | Yes | No |
| 17540947 | ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS | December 2021 | January 2024 | Allow | 26 | 1 | 1 | No | No |
| 17526883 | ANTI-TLR4 ANTIBODIES AND USES THEREOF | November 2021 | October 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17450282 | ANTI-NOTCH3 ANTIBODY | October 2021 | February 2025 | Allow | 40 | 4 | 0 | No | No |
| 17493938 | PROTEIN-BASED PURIFICATION MATRICES AND METHODS OF USING THE SAME | October 2021 | November 2022 | Allow | 13 | 3 | 0 | Yes | No |
| 17489391 | FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY | September 2021 | June 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17472004 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS | September 2021 | September 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17397287 | INTERLEUKIN-4 RECEPTOR-BINDING FUSION PROTEINS AND USES THEREOF | August 2021 | January 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17396792 | METHODS AND REAGENTS FOR MODULATING MACROPHAGE PHENOTYPE | August 2021 | February 2024 | Allow | 30 | 1 | 0 | No | No |
| 17397447 | Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Colorectal Cancer | August 2021 | July 2024 | Allow | 36 | 2 | 1 | No | No |
| 17396351 | Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist | August 2021 | June 2024 | Allow | 34 | 1 | 1 | No | No |
| 17427581 | HALF-LIFE EXTENDED IMMTAC BINDING CD3 AND A HLA-A*02 RESTRICTED PEPTIDE | July 2021 | June 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17423999 | ANTI-ELASTIN ANTIBODIES AND METHODS OF USE | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17377297 | NUCLEIC ACID FOR TREATING MITE ALLERGY | July 2021 | December 2021 | Allow | 5 | 1 | 0 | Yes | No |
| 17376233 | ANTI-IL-36R ANTIBODIES FOR THE TREATMENT OF PYODERMA GANGRENOSUM | July 2021 | August 2024 | Allow | 37 | 1 | 1 | No | No |
| 17372575 | PROTEIN SIGNATURES FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS | July 2021 | March 2024 | Allow | 32 | 1 | 0 | No | No |
| 17346421 | ANTI-IL31RA ANTIBODY-CONTAINING FORMULATIONS | June 2021 | November 2021 | Allow | 5 | 0 | 0 | No | No |
| 17413045 | ANTI-HUMAN INTERLEUKIN 5(IL-5) MONOCLONAL ANTIBODY AND USE THEREOF | June 2021 | April 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17299239 | REGULATABLE CELL SURFACE RECEPTORS AND RELATED COMPOSITIONS AND METHODS | June 2021 | June 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17330716 | COMBINATION THERAPY FOR TREATMENT OF DISEASE | May 2021 | December 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17320128 | ANTI-JAGGED1 ANTIGEN BINDING PROTEINS | May 2021 | September 2023 | Allow | 29 | 1 | 1 | No | No |
| 17317789 | Methods for Treating Multiple Myeloma | May 2021 | November 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 17317252 | MUTANT OF RANKL AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING OSTEOPOROSIS | May 2021 | October 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17289201 | RETINAL GANGLION CELL DEATH INHIBITOR | April 2021 | July 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17236467 | ANTIBODY CONSTRUCTS FOR DLL3 AND CD3 | April 2021 | January 2025 | Allow | 45 | 2 | 1 | No | No |
| 17286359 | METHOD FOR DETERMINING GLOMERULAR FILTRATION ABILITY | April 2021 | March 2025 | Allow | 47 | 1 | 1 | No | No |
| 17284379 | COMPOUNDS AND THERAPEUTIC USES THEREOF | April 2021 | March 2025 | Allow | 47 | 1 | 1 | No | No |
| 17214585 | METHOD OF TREATING AN AUTOIMMUNE DISEASE BY ADMINISTERING AN ANTI-HUMAN BAFF ANTIBODY | March 2021 | November 2024 | Abandon | 43 | 3 | 1 | No | No |
| 17198404 | PREFILLED SYRINGE WITH PEGFILGRASTIM HAVING OPTIMIZED DOSE AND METHODS RELATED THERETO | March 2021 | July 2022 | Allow | 16 | 3 | 0 | No | No |
| 17188912 | BTLA FUSION PROTEIN AGONISTS AND USES THEREOF | March 2021 | November 2023 | Allow | 32 | 1 | 1 | No | No |
| 17179212 | ENHANCED RECONSTITUTION AND AUTORECONSTITUTION OF THE HEMATOPOIETIC COMPARTMENT | February 2021 | December 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17267066 | ANTIBODIES THAT BIND CD277 AND USES THEREOF | February 2021 | June 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17169182 | COMPOSITIONS FOR TREATMENT OF DISORDERS | February 2021 | June 2024 | Allow | 41 | 1 | 0 | No | No |
| 17156407 | ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS | January 2021 | August 2021 | Allow | 7 | 1 | 0 | No | No |
| 17154620 | METHOD OF TREATING ANOREXIA USING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | January 2021 | July 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17153229 | Serum Albumin-Binding Fibronectin Type III Domains | January 2021 | July 2023 | Allow | 30 | 1 | 0 | No | No |
| 17145549 | Biomarkers for Diagnosis and Prognosis of Corneal Ectatic Disorders | January 2021 | June 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17128955 | TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE | December 2020 | June 2024 | Allow | 42 | 1 | 0 | No | No |
| 17127755 | ANTI-BAFFR ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | December 2020 | March 2024 | Allow | 39 | 2 | 0 | No | No |
| 17126500 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS | December 2020 | October 2021 | Abandon | 10 | 1 | 0 | No | No |
| 17124141 | TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA | December 2020 | April 2024 | Abandon | 40 | 2 | 0 | No | No |
| 17251663 | APJ ANTIBODY, FUSION PROTEIN THEREOF WITH ELABELA, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOFus01 | December 2020 | November 2024 | Allow | 47 | 1 | 1 | Yes | No |
| 17112664 | ANTIBODIES THAT BIND INTERLEUKIN-2 AND USES THEREOF | December 2020 | October 2024 | Allow | 46 | 3 | 1 | No | No |
| 17110004 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | December 2020 | November 2021 | Allow | 12 | 0 | 0 | Yes | No |
| 17102189 | NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES | November 2020 | May 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17090237 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RADIATION-RELATED DISORDERS | November 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17053256 | Anti-BCMA Antibody And Use Thereof | November 2020 | January 2025 | Allow | 50 | 2 | 1 | No | No |
| 17089433 | METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA | November 2020 | February 2024 | Abandon | 40 | 1 | 1 | No | No |
| 17072434 | SYNTHETIC NOTCH RECEPTOR PROTEIN FOR MODULATING GENE EXPRESSION | October 2020 | April 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 16980237 | MODIFICATION OF IMMUNE CELLS FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY | September 2020 | December 2023 | Allow | 39 | 1 | 1 | No | No |
| 16979707 | CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY | September 2020 | January 2024 | Abandon | 40 | 2 | 1 | No | No |
| 16971559 | TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND ITS BINDING PARTNER | August 2020 | May 2024 | Abandon | 45 | 0 | 1 | No | No |
| 16997282 | TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR | August 2020 | September 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16970792 | METHODS OF REGULATORY T CELL EXPANSION AND ACTIVATION | August 2020 | September 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16970034 | METHODS AND COMPOSITIONS FOR TREATING VITILIGO | August 2020 | November 2024 | Abandon | 51 | 3 | 1 | No | No |
| 16969733 | PROCESS FOR PRODUCING HU14.18K322A MONOCLONAL ANTIBODY | August 2020 | February 2025 | Abandon | 54 | 2 | 0 | No | No |
| 16992897 | ANTI-NOTCH3 ANTIBODIES | August 2020 | November 2024 | Allow | 51 | 4 | 0 | No | No |
| 16992068 | INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF | August 2020 | February 2023 | Allow | 30 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BUNNER, BRIDGET E.
With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BUNNER, BRIDGET E works in Art Unit 1647 and has examined 1,123 patent applications in our dataset. With an allowance rate of 55.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner BUNNER, BRIDGET E's allowance rate of 55.1% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BUNNER, BRIDGET E receive 1.52 office actions before reaching final disposition. This places the examiner in the 38% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BUNNER, BRIDGET E is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +29.7% benefit to allowance rate for applications examined by BUNNER, BRIDGET E. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.9% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 52.9% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 79.2% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 81.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 70.2% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 7.3% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.5% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.